A visual approach to the economic evaluation of vaccines: opening the health economic black box

References

• Department of Health and Social Care (DHSC). Cost-effectiveness methodology for vaccination programmes: consultation on the cost-effectiveness methodology for vaccination programmes and procurement (CEMIPP) report. London: Department of Health and Social Care; 2018. [cited 2021 Mar 04]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/707847/cemipp-consultation-document.pdf.
   Google Scholar
• PlacingThePublic.lshtm.ac.uk/[Internet]. London (UK): London school of hygiene & tropical medicine. Vaccine and celebrity – the meningitis B vaccine debate in context; 2016 Mar 7. [cited 2021 Mar 04]. Available from: https://placingthepublic.lshtm.ac.uk/2016/03/07/vaccination-and-celebrity-the-meningitis-b-vaccine-debate-in-context/.
   Google Scholar
• Gallagher J. Meningitis B vaccine: hearts v heads. BBC [Internet]. 2016 Mar 2 [accessed 2020 Apr]; Health. Available from: https://www.bbc.co.uk/news/health-35706020.
   Google Scholar
• Griffiths JP, Crowe S, Pagel C, et al. A method for evaluating and comparing immunisation schedules that cover multiple diseases: illustrative application to the UK routine childhood vaccine schedule. Appendix B: a method to calculate the loss of quality-adjusted-life-years (QALYs) due to an episode of a disease across 12 vaccine-preventable diseases of childhood. Vaccine. 2018;36(35):5340–5347.
   PubMed Web of Science ®Google Scholar
• Al-Janabi H, Van Exel J, Brouwer W, et al. A framework for including family health spillovers in economic evaluation. Med Decis Making. 2016;36(2):176–186.
   PubMed Web of Science ®Google Scholar
• Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, et al. Valuing vaccination. Proc Natl Acad Sci. 2014;111(34):12313–12319.
   PubMed Web of Science ®Google Scholar
• Jit M, Hutubessy R. Methodological challenges to economic evaluations of vaccines: is a common approach still possible? Appl Health Econ Health Policy 2016;14(3):245–252.
   PubMed Web of Science ®Google Scholar
• Jit M, Hutubessy R, Png ME, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13(1):1–9.
   PubMedGoogle Scholar
• Lakdawalla DN, Doshi JA, Garrison LP, et al. Defining elements of value in health care—a health economics approach: an ispor special task force report [3]. Value Health. 2018;21(2):131–139.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease 2004 Update: disability weights for diseases and conditions. Geneva: World Health Organization (WHO); 2004. [cited 2021 Mar 4]. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf.
   Google Scholar
• Murray CJL, Lopez AD. Global Burden of Disease and Injury Series. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston (MA): Harvard School of Public Health, on behalf of the World Health Organization and the World Bank, 1996. p. 117–200.
   Google Scholar
• Trueman D. Will discount rates change for UK HTA? Source Health Economics [Internet 2019 Mar 19th. Available from: https://www.source-he.com/post/2019/03/19/have-discount-rates-changed-for-uk-hta
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. NICE; 2013. Available from: guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781(nice.org.uk)
   Google Scholar
• Scottish Medicines Consortium (SMC). Working with SMC – a Guide for manufacturers. SMC; 2017. [cited 2021 Mar 4]. Available from: https://www.scottishmedicines.org.uk/media/5498/working-with-smc-updated-october-2020.pdf
   Google Scholar
• Rakhmanova AG, Nosikova E, Tanasijchuk T, et al. Diphtheria Outbreak in St. Petersburg: clinical Characteristics of 1,860 Adult Patients. Scand J Infect Dis. 1996;28:37–40.
   PubMed Web of Science ®Google Scholar
• Naghavi M, Abolhassani F, Pourmalek F, et al. The burden of disease and injury in Iran 2003. Population Health Metr. 2009;7:9.
   PubMedGoogle Scholar
• Atkinson W, Wolfe S, Hamborsky J. Tetanus. Centers for Disease Control and Prevention. Tetanus. In: Atkinson W, Wolfe S, Hamborsky J., editors. Epidemiology and prevention of vaccine-preventable diseases. Washington (DC): Centers for Disease Control and Prevention. Public Health Foundation; 2012. p. 291–300.
   Google Scholar
• Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis. 2000;31:85–95.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Murray CJL. Poliomyelitis. In: Murray CL, Lopez AD, Mathers CD, editors. The global burden of disease and injuries series, volume 4: the global epidemiology of infectious diseases. Geneva: World Health Organization (WHO); 2004. p. 111–149.
   Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–4214.
   PubMed Web of Science ®Google Scholar
• Atkinson W, Wolfe S, Hamborsky J, et al. editors. Epidemiology and prevention of vaccine-preventable diseases. 11th, Washington:Centers for Disease Control and Prevention (CDC). Public Health Foundation. 2009.
   Google Scholar
• Dworkin MS, Park L, Borchardt SM. The changing epidemiology of invasive haemophilus influenzae disease, especially in persons > or= 65 years Old. Clin Infect Dis. 2007;44:810–816.
   PubMed Web of Science ®Google Scholar
• Senecal M, Brisson M, Lebed MH Burden of rotavirus associated gastroenteritis in Canadian families: a prospective community based study. Poster session presented at: Seventh Canadian Immunization Conference; 2006 Dec 3-6; Winnipeg, CA.
   Google Scholar
• Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ. 2008;11:471–484.
   PubMedGoogle Scholar
• Public Health England (PHE). Invasive meningococcal disease in England: annual report for 2017 to 2018 supplementary data tables. London (UK): PHE; 2018. (PHE publications; no. 2018571). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/752085/Laboratory_confirmed_cases_of_IMD_England_data_tables_2017to2018.pdf.[Accessed 2019 Dec]
   Google Scholar
• Christensen H, Hickman M, Edmunds WJ, et al. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31:2638–2646.
   PubMed Web of Science ®Google Scholar
• Public Health England (PHE). Rotavirus data 2007 to 2016. London (UK): PHE; 2018. (PHE publications; no. 2018070). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/711983/rotavirus_data_2007_to_2016_may_2018.pdf. [Accessed 2019 Dec].
   Google Scholar
• World Bank [Internet]. Life Expectancy at Birth, total (years) – United Kingdom (2017). [cited 2021 Mar 04]. Available from: https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=GB.
   Google Scholar
• Jit M, Pebody R, Chen M. Estimating the number of deaths with rotavirus as a cause in England and Wales. Hum Vaccine. 2007;3:23–26.
   PubMed Web of Science ®Google Scholar
• Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine. 2007;25(20):3971–3979.
   PubMed Web of Science ®Google Scholar
• Mokiou S, Standaert B, Li X, et al. Measuring the cost of a pediatric vaccine administration in the UK. Vaccine. 2008;36:237–242.
   Google Scholar
• NIHR Evidence [Internet]. London (UK): National Institute for Health Research. Rotavirus vaccine estimated to have saved the NHS £12.5 million a year; 2017 Feb 21. Available from: https://discover.dc.nihr.ac.uk/content/signal-000388/rotavirus-vaccine-estimated-to-have-saved-the-nhs-12-5-million-a-year.
   Google Scholar
• Sagonowsky E GSK finally seals U.K. Bexsero deal for £20 per dose, report says. FiercePharma [Internet]. 2015 Mar 30; Vaccines. Available from: https://www.fiercepharma.com/vaccines/gsk-finally-seals-u-k-bexsero-deal-for-%C2%A320-per-dose-report-says.
   Google Scholar
• GSK (November 2018). GSK vaccine products. [cited 2021 Mar 04]. Available from: https://www.dispensingdoctor.org/wp-content/uploads/2018/11/gsk-vaccine-products-november-data.pdf.
   Google Scholar
• Department of Health (DH). Immunisation against infectious disease. [The ‘Green Book’.]. London (UK): Public Health England. 2013. Chapter 27b, Rotavirus: Chapter 27b 329–341. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/457263/Green_Book_Chapter_27b_v3_0.pdf.2013
   Google Scholar
• Szabo SM, Johnston KM, Lloyd AJ. Advanced data visualisation in health economics and outcomes research: opportunities and challenges. Appl Health Econ Health Policy. 2019;17:433–441.
   PubMed Web of Science ®Google Scholar